title: Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment.
abstract: There has been enormous progress this past decade in the understanding of the biology of dendritic cells (DCs) along with increasing attention for the development of novel dendritic cell (DC)-based cancer therapies. However, the clinical impact of DC-based vaccines remains to be established. This limited success could be explained by suboptimal conditions for generating potent immunostimulatory DCs as well as immune suppression mediated by the tumor microenvironment (TME). Therefore, strategies that optimize the potency of DC vaccines along with newly described therapies that target the TME in order to overcome immune dysfunction may provide durable tumor-specific immunity. These novel interventions hold the most promise for successful cancer immunotherapies.
authors: Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA.
authors: Anne
authors: A
authors: Gallois
authors: Nina
authors: N
authors: Bhardwaj
keywords: cancer; dendritic cells; immune checkpoints; immunotherapy; tumor microenvironment